Location:Home / Journals / Article Detail

International Journal of Clinical and Experimental Medicine Research


PDF Download

Cytokine Varieties and Cytokine Storms in COVID-19: A Review

A. S. M. Giasuddin1,*, K. A. Jhuma1, R. S. Giasuddin2, W. A. Chowdhury1

1Impulse Hospital, ImHS&RCLtd, 304/E Tejgaon Industrial Area, Dhaka-1208, Bangladesh.

2Department of Medicine, Anwer Khan Modern Medical College, Road No. 8A, Dhanmondi, Dhaka-1205, Bangladesh.

*Corresponding author: A. S. M. Giasuddin

Date: November 29,2021 Hits: 2095


Cytokines are heterogeneous group of protein cell regulators having many (pleotropic) activities produced by a wide variety of cells in the body. They have made tremendous impact in clinical medicine as well as laboratory medicine. Therapeutic impacts of cytokines have been felt in the areas of cancer, infectious diseases, blood disorders, rheumatic and autoimmune diseases mainly. Quantitative determination of the levels of various cytokines in blood and other body fluids were found to be useful in order to monitor disease activity or monitor treatment or evaluate the need for treatment. The infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is termed as Corona Virus Disease 2019 (COVID-19). This new virus and the disease were unknown before the outbreak in Wuhan, China in December 2019. Clinical presentations of COVID-19 are a vast spectrum ranging from asymptomatic carriers to critically ill patients with multi organ failure needing multiple life supports. After the virus gains entry into the body through the mucus membrane, massive amounts of cytokines production i.e. cytokine storms occur which play a pivotal role behind COVID-19 pathophysiology in severe and critically ill patients. The cytokines involved are IL-1, IL-2, IL-6, IL-7, IL-8, IL-10, IL-17, IFN-α, IFN-γ, G-CSF, GM-CSF, TNF-α, TNF-β, MCP-1, MIP1A, etc. Potentially dangerous complications may occur which demand that highly trained and well-informed clinicians, nursing staff and laboratory medicine manpower are available where cytokines are to be introduced either as therapy or clinical trial. Some recent aspects of these cytokine varieties and cytokine storms in COVID-19 were discussed in this review article.


[1] Balkwill, F. R., Burke, F. (1989). The cytokine networks. Immunology Today, 10: 299-302.

[2] Chapel, H., Haeney, M., Mishbah, S., Snowden, N. (Eds). (2014). Essentials of Clinical Immunology. 6th Edition; UK: Wiley Blackwell Publication.

[3] Giasuddin, A. S. M., Ziu, M. M. (1996). Views for future development of cytokines in health and disease: Implications for clinical medicine. Journal of Islamic Academy of Sciences, 9(3): 67-74.

[4] Callard, R. E., Mathews, D. J., Hibbet. I. (1996). IL-4 and IL-13 receptors; are they one and the same? Immunology Today, 17:108-110.

[5] Burtis, C. A., Bruns, D. E., Sawyer, B. G. (Eds). Tietz Fundamentals of Clinical Chemistry and Molecular Biology, 7th Edition; ST. Louis, Missouri (USA): Elsevier Saunders, 2015.

[6] Romagnani, S. (1991). Human TH1 and TH2 subsets; doubt no more? Immunology Today, 12: 256-257.

[7] Adorini, L., Sinigaglia, F. (1997). Pathogenesis and immunotherapy of autoimmune diseases. Immunology Today, 18: 209-211.

[8] Symposium on “Future directions of cytokines and immunoglobulin therapy (nine review articles)”. (1992). Clinical Immunology and Immunopathology, 62: S1-S65.

[9] Billiau, A., Dijkmans, R. (1990). Interferon gamma: mechanism of action and therapeutic potential. Biochemical Pharmacology, 40: 1433-1441.

[10] Rusell, S. J. (1990). Lymphokine gene therapy for cancer. Immunology Today, 11: 196-201.

[11] Arend, W. P., Dayer, J. M. (1990). Cytokines and cytokine inhibitors or antagonists in rheumatic arthritis. Arthritis and Rheu-matism, 33: 305-312.

[12] WHO Director-General’s opening remarks at the media briefing on COVID-19: March 2020. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19%2D%2D-11- march-2020.

[13] Naming the coronavirus disease (COVID-19) and the virus that causes it: 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the- virus-that-causes-it.

[14] Coronavirus Disease 2019 (COVID-19) Situation Report 96: 2020. Available from: https://www.who.int/docs/default-source/ coronaviruse/situation-reports/20200425-sitrep-96-covid19.pdf.

[15] Lorenz, C., Azevedo, T. S., Chiaravalloti-Neto, F. (2020). COVID-19 and dengue fever: A dangerous combination for the health system in Brazil. Travel Medicine and Infectious Disease, 35: 101659. https://doi:10.1016/j.tmaid.2020.101659.

[16] Walls, A. C., Park, Y-J, Tortorici, M. A., Wall, A., McGuire, A. T., Veesler, D. (2020). Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell, 181(2): 281-292.e6.

[17] Astuti, I., Srafil, Y. (2020). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes and Metabolic Syndrome, 14(4): 407-412. Doi: 10.1016/j.dsx.2020.04.020. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165108/.

[18] Zhang, J-j, Dong, X, Cao, Y-y, Yuan, Y-d, Yan, Y-B, Yan, Y-Q, et al. (2020). Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy, 75(7): 1730-1734. https://doi: 10.1111/all.14238.

[19] Gandhi, R. T., Lynch, J. B., del Rio, C. (2020). Mild or moderate Covid-19. New England Journal of Medicine, 383(18): 1757-1766. Available from: http://www.nejm.org/doi/10.1056 / NEJMcp2009249.

[20] Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19), 2020. Available from: https://www.who.int/publications-detail/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19).

[21] Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., et al. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 181: 271-280.e8.

[22] Zhang, C., Wu, Z., Li, J.-W., Zhao, H., Wang, G.-Q. (2020). Cytokine release syndrome (CRS) in severe COVID-19: Interleu-kin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce mortality. International Journal of Antimicrobial Agents, 55(5): 105954. https://doi.org/10.1016/j.ijantimicag.2020.105954.

[23] Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., Manson, J. J. (2020). COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet, 395: 1033-34.

[24] Rahmati, M. (2020). Cytokine-targeted therapy in severely ill COVID-19 patients: options and cautions. Eurasian Journal of Medical Oncology, Available from: https://www.ejmo.org/10.14744/ ejmo.2020.72142.

[25] Leisman, D. E., Deutschman, C. S., Legrand, M. (2020). Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Medicine, 46: 1-4. Available from: http://link.springer.com/10.1007/s00134-020- 06059-6.

[26] Li, B., Feng, F., Yang, G., Liu, A., Yang, N., Jiang, Q., et al. (2020). Immunoglobulin G/M and cytokines detections in conti-nuous sera from patients with novel coronaviruses (2019-nCoV) infection. Rochester, NY: Social Science Research Network, 2020 Fed/ Report No.: ID 3543609. Available from: https://papers.ssrn.com/ abstract=3543609.

[27] Zhou, Y., Fu, B., Zheng, X., Wang, D., Zhao, C., Qi, Y., et al. (2020). Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. National Science Review, 7(6): 998-1002. Available from: https://doi.org/10.1093/nsr/nwaa041/5804736.

[28] Zheng, H.-Y., Zhang, M., Yang, C.-X., Zhang, N., Wang, X.-C., Yang, X.-P., et al. (2020). Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cellular and Molecular Immunology, 17: 541-543.

[29] Wu, Z., McGoogan, J. M. (2020). Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a Report of 72314 cases from the Chinese Center for Disease Control and Prevention. Journal of American Medical Association, 323(13): 1239-1242. https://doi:10.1001/jama.2020.2648.

[30] Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., et al. (2020). Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell, 181(5): 1036-1045.e9. https://doi:10.1016/j.cell.2020.04.026 (2020).

[31] Lippi, G., Plebani, M., Henry, B. M. (2020). Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clinica Chemica Acta, 506: 145-148. https://doi:10.1016/j.cca.2020.03.022.

[32] Guan, W.-j, Ni, Z.-yi, Hu, Y, Liang, W.-h, Ou, C.-q, He, J.-x, et al. (2020). Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine, 382: 1708-1720. https://DOI:10.1056/NEJMoa2002032.

[33] Costela-Ruiz, V. J., Illesces-Montes, R., Puerta-Puerta, J. M., Ruiz, C., Melguizo-Rodriguez. L. (2020). SARS-Cov-2 infection: The role of cytokines in COVID-19 disease. Cytokine and Growth Factor Reviews, 54: 62-75. https://doi:10.1016/cytogfr2020.06.001.

[34] Du, R.-H., Liang, L.-R., Yang, C.-Q., Wang, W., Cao, T.-z, Li. M., et al. (2020). Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. European Respiratory Journal, 55(5): 2000524; https://doi:10.1183/13993003.00524-2020.

[35] Wang, K., Zuo, P., Liu, Y., Zhang, M., Zhao, X., Xie, S., et al. (2020). Clinical and laboratory predictors of in-hospital mortality in patients with COVID-19: a cohort study in Wuhan, China. Clinical Infectious Diseases, 71(16): 2079-2088. https://doi.org/:10.1093/cid/ciaa538.

[36] Moore, J. B., June, C. H. (2020). Cytokine release syndrome in severe COVID-19. Science, 368: 473-474. https://doi:10.1126/science. abb8925.

[37] Diao, B., Wang, C., Tan, Y., Chen, X., Liu, Y., Ning, L., et al. (2020). Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Frontiers in Immunology, 11: 827. https://doi:10.3389/fimmu.2020.00827.

[38] Henrina, J., Putra, I. C. S., Lawrensea, S., Handoyono, Q. F., Cahyadi, A. (2020). Coronavirus disease of 2019: A mimicker of dengue infection? SN Comprehensive Clinical Medicine, 2: 1109-1119. Available from: https://doi.org/10.1007/s42399-020-00364-3.

[39] Adikari, T. N., Gomes, L., Wickramasinghe, N., Salimi, M., Wijesiriwardana, N., Kamaladasa, A., et al. (2016). Dengue NS1 antigen contributes to disease severity by inducing interleukin (IL)-10 by monocytes. Clinical and Experimental Immunology, 184(1): 90-100. https://doi:10.1111/cei.12747.

[40] Blumberg, N., Spinelli, S. L., Francis, C. W., Taubman, M. B., Phipps, R. P. (2009). The platelet as an immune cell-CD40 ligand and transfusion immunomodulation. Immunologic Research, 45(2-3): 251-260. https://doi:10.1007/s12026-009-8106-9.

[41] Wichmann, D., Sperhake, J.-P., Lutgehetmann, M., Steurer, S., Edler, C., Heinemann, A., et al. (2020). Autopsy findings and venous thromboembolism in patients with COVID-19. Annals of Internal Medicine, M20-2003. https://doi:10.7326/M20-2003.

Full-Text HTML

Cytokine Varieties and Cytokine Storms in COVID-19: A Review

How to cite this paper: A. S. M. Giasuddin, K. A. Jhuma, R. S. Giasuddin, W. A. Chowdhury. (2022) Cytokine Varieties and Cytokine Storms in COVID-19: A ReviewInternational Journal of Clinical and Experimental Medicine Research6(1), 16-23.

DOI: http://dx.doi.org/10.26855/ijcemr.2022.01.004